Anticorps Polyclonal de lapin anti-CYLD

• Phare
• Validé par KD/KO

CYLD Polyclonal Antibody for IHC, IP, WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IP, IHC, IF, ELISA

Conjugaison

Non conjugué

Publications

21

N° de cat : 11110-1-AP

Synonymes

CDMT, CYLD, CYLD1, CYLDI, Deubiquitinating enzyme CYLD, EAC, HSPC057, KIAA0849, MFT, MFT1, SBS, TEM, Ubiquitin thiolesterase CYLD, USPL2

---

Galerie de données de validation

• 

  WB analysis using 11110-1-AP

  mouse brain tissue were subjected to SDS PAGE followed by western blot with 11110-1-AP (CYLD antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Jurkat using 11110-1-AP

  Jurkat cells were subjected to SDS PAGE followed by western blot with 11110-1-AP (CYLD antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 11110-1-AP

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 11110-1-AP (CYLD antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of A431 using 11110-1-AP

  A431 cells were subjected to SDS PAGE followed by western blot with 11110-1-AP (CYLD antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of A431 using 11110-1-AP

  A431 cells were subjected to SDS PAGE followed by western blot with 11110-1-AP (CYLD antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of mouse brain using 11110-1-AP

  mouse brain tissue were subjected to SDS PAGE followed by western blot with 11110-1-AP (CYLD antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  IP experiment of mouse brain using 11110-1-AP

  IP Result of anti-CYLD (IP:11110-1-AP, 4ug; Detection:11110-1-AP 1:300) with mouse brain tissue lysate 4000ug.

• 

  IHC staining of human colon cancer using 11110-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer using 11110-1-AP (CYLD antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human colon cancer using 11110-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer using 11110-1-AP (CYLD antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human colon using 11110-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon using 11110-1-AP (CYLD antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human colon using 11110-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon using 11110-1-AP (CYLD antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human brain using 11110-1-AP

  Immunohistochemical analysis of paraffin-embedded human brain using 11110-1-AP (CYLD antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human brain using 11110-1-AP

  Immunohistochemical analysis of paraffin-embedded human brain using 11110-1-AP (CYLD antibody) at dilution of 1:50 (under 40x lens).

---

Applications testées

• Résultats positifs en WB: tissu cérébral de souris, cellules A431, cellules HEK-293, cellules Jurkat
• Résultats positifs en IP: tissu cérébral de souris
• Résultats positifs en IHC: tissu de cancer du côlon humain, tissu cérébral humain, tissu de côlon humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:2000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunohistochimie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 6 publications below
• WB: See 20 publications below
• IHC: See 5 publications below
• IF: See 1 publications below
• IP: See 1 publications below

Informations sur le produit

11110-1-AP cible CYLD dans les applications de WB, IP, IHC, IF, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Réactivité citée: rat, Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: CYLD Protéine recombinante Ag1598
• Nom complet: cylindromatosis (turban tumor syndrome)
• Masse moléculaire calculée: 107 kDa
• Poids moléculaire observé: 110 kDa
• Numéro d’acquisition GenBank: BC012342
• Symbole du gène: CYLD
• Identification du gène (NCBI): 1540
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

CYLD, also named as CYLD1, belongs to the peptidase C67 family. It is the protease that specifically cleaves 'Lys-63'-linked polyubiquitin chains. CYLD has endodeubiquitinase activity and plays an important role in the regulation of pathways leading to NF-kappa-B activation. CYLD contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation. It is a negative regulator of Wnt signaling. CYLD inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules. CYLD plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis. It is required for normal cell cycle progress and normal cytokinesis. CYLD inhibits nuclear translocation of NF-kappa-B and plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation. It is dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. CYLD negatively regulates TNFRSF11A signaling and osteoclastogenesis. This antibody is a rabbit polyclonal antibody raised against residues near the C terminus of human CYLD.

Publications

Species	Application	Title
human	WB	Nat Cell Biol; TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination.; Authors - Guixin Zhu ; KD Validated
human	IHC	Cancer Lett; CYLD deficiency enhances metabolic reprogramming and tumor progression in nasopharyngeal carcinoma via PFKFB3.; Authors - Lingzhi Wang
rat	WB	Arterioscler Thromb Vasc Biol; CYLD Deubiquitinates Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 Contributing to Adventitial Remodeling.; Authors - Bing Yu
human	WB	Sci Total Environ; USP15 participates in DBP-induced testicular oxidative stress injury through regulating the Keap1/Nrf2 signaling pathway.; Authors - Lei Zhang ; KD Validated
human	WB	iScience; Centrosomal protein 120 promotes centrosome amplification and gastric cancer progression via USP54-mediated deubiquitination of PLK4; Authors - Chenggang Zhang
human	WB,IHC	Chem Biol Interact; miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD.; Authors - Jaceline Sanches ; KD Validated

Produits associés

NFKB1,p105,p50 Polyclonal antibody

14220-1-AP

IKBKG Polyclonal antibody

18474-1-AP

ubiquitin Polyclonal antibody

10201-2-AP

TRAIL Polyclonal antibody

17235-1-AP

PLK1 Polyclonal antibody

10305-1-AP

SMARCE1 Polyclonal antibody

10814-1-AP